15 April 2020

Moderna has begun enrolment of participants for the highest dose arm of the Phase I clinical trial assessing its mRNA-1273 vaccine candidate against Covid-19. Led by the US National Institutes of Health (NIH), the trial is designed to include arms for 25μg, 100μg and 250μg dose levels of mRNA-1273.

Merck Group subsidiary MilliporeSigma has agreed to support The Jenner Institute in Oxford, UK, in the large-scale manufacturing of the latter’s Covid-19 vaccine candidate, ChAdOx1 nCoV-19. The partners worked together to cut the manufacturing process time from approximately 6-12 months to two months.

NantKwest and ImmunityBio are in discussions with the US Food and Drug Administration (FDA) regarding the development of Covid-19 vaccines and therapeutics. The collaboration combines ImmunityBio’s vaccine development and natural killer cell activation capabilities with NantKwest’s off-the-shelf, cell-based therapeutics expertise. Read the full story here

Clara Health has partnered with Lyft and public relations firm VSC to launch an initiative to enhance Covid-19 participation by matching patients to relevant clinical trials. Clara Health developed a registry platform and database called World Without COVID, which lists more than 300 Covid-19 trials; the database is open for researchers and public.